Calliditas Therapeutics launches proposed global offering
Search jobs
Calliditas Therapeutics launches proposed global offering
January 26, 2021
Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX; Nasdaq – CALT) will today launch a proposed public offering of American Depositary Shares ( ADSs ), in the United States for trading on The Nasdaq Global Select Market in the United States (the “U.S. Offering”) and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States (the Private Placement”, and together with the U.S. Offering, the “Global Offering”). The target size of the Global Offering is 4,500,000 common shares plus a potential 30-day over-allotment option of 15 percent of the common shares (including common shares in the form of ADSs) offered by Calliditas at the U.S. Offering price. The Global Offering is subject to market conditions and investor demand and
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of .
Zealand PharmaJanuary 27, 2021 GMT
Company announcement – No. 2 / 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FIN
Calliditas Therapeutics launches proposed global offering
News provided by
Share this article
Calliditas Therapeutics AB (publ) ( Calliditas ) (Nasdaq OMX: CALTX) (Nasdaq: CALT)
will today launch a proposed public offering of American Depositary Shares ( ADSs ), in the United States for trading on The Nasdaq Global Select Market in the United States (the U.S. Offering ) and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States (the Private Placement , and together with the U.S. Offering, the Global Offering ). The target size of the Global Offering is 4,500,000 common shares plus a potential 30-day over-allotment option of 15 percent of the common shares (including common shares in the form of ADSs) offered by Calliditas at the U.S. Offering price. The Global Offering is subject to market conditions and investor demand and the number of ADSs (which represents two common shares) and common shar